walgreen seek bolster profit
updat forecast estim jul
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jul
estim jul
price data jul
rate updat jul
currenc amount express
valuat growth profit
methodolog valu compani
walgreen one success retail oper
sinc found remain major player within
pharmaceut suppli chain mani decad firm
process approxim total prescript
fiscal make one largest retail pharmaci
acquisit europe-bas allianc boot firm
premier global retail powerhous nevertheless believ
walgreen face pressur oper environ given
rapidli grow price power larg pharmaci benefit
manag pbm abl aggreg enorm amount
claim volum leverag power price negoti
walgreen tri off-set headwind drive sale volum
consolid sell nonnpharmaceut
product opinion demonstr weaker posit
along pharmaceut suppli chain walgreen tri
counter pressur retail pharmaci oper environ
cosmet groceri household conveni good
strategi also put firm even direct competit
vast array retail sector profit outsiz
return invest capit hard come
posit note firm recent receiv regulatori approv
acquisit half store fleet solidifi
walgreen largest retail pharmaci chain
acquisit increas volum geograph reach
also materi augment global gener purchas volum
walgreen also better-posit build prefer
pharmaci strategi strategi entail retail pharmaci
discount gener drug inventori becom prefer
pharmaci pbm retail network drive store foot traffic
strategi promis walgreen yet report
improv same-stor compar result front-end
product addit firm struggl compress
gross margin last hand year believ
trend directli reflect steep headwind face pharmaci
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
walgreen nation largest retail pharmaci approxim
drugstor throughout unit state firm recent acquir
half locat increas store count scale
larg network store enabl firm reach signific portion
 popul provid excel brand recognit prescript
drug account two third sale balanc attribut
front-stor product groceri health beauti item
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
valuat growth profit jul
fair valu estim walgreen
factor acquisit approxim rite aid
store walgreen acquir total number
store initi sought action allow
firm move larger store count also
particip sourc remain gener inventori
wbad partnership ad volum
lucr joint ventur lower gener cost given
circumst believ correct cours
action think firm like reap
value-cr synergi deal howev remain
cautiou firm success integr asset
network given underinvest natur
rite aid store asset overal action modestli
posit dcf valuat also believ firm
continu produc solid long-term valu gener
sourc joint ventur boast
express script member
perspect recent strateg partnership
walgreen close allow gain greater
distribut effici enhanc manufactur price
leverag ultim lead increas profit
next year forecast adjust prescript
increas moder driven firm prefer
pharmaci strategi shift demograph
increas pharmaceut usag healthcar benefit
payer flat prescript drug price offset dynam
gener becom greater percentag prescript
fill payer look way hold overal cost
employe benefit check also project firm
sale front-stor product nonpharmaceut good
grow line overal growth mix
averag oper margin rang
explicit forecast
scenario analysi take consider effect
custom supplier price negoti leverag
overal demand use pharmaceut product
prefer pharmaci strategi success walgreen
front-end product sale strategi bull-cas scenario
factor less price profit pressur due
custom price demand increas supplier price
leverag addit factor acceler growth
prescript front-stor product assum
success front-stor sale strategi scenario
fair valu estim increas
bear case assum firm face even price
pressur drug benefit plan payer alreadi
order preserv prefer pharmaci posit
addit assum secular trend boost
secular pharmaceut demand strong
initi believ firm front-stor strategi fail
boost nonprescript product sale averag
growth scenario fair valu estim
decreas
obtain moat retail pharmaci industri extrem
tough believ walgreen
possess econom moat confluenc price
pressur major pharmaci custom drug benefit plan
mass grocer retail heavi depend
nonpharmaceut front-stor product profit
steadili push firm return invest capit
downward fact roic adjust oper leas
steadili fallen toward firm adjust weight averag
cost capit past five year
forese signific recoveri metric believ
return remain trajectori
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
believ walgreen stabl moat trend even though
firm may possess competit advantag
consist produc econom profit believ
remain key player within healthcar space
player along pharmaceut suppli
chain signific leverag walgreen
believ enough valu firm vast network
retail locat ensur stabl moat trend firm
extens retail footprint conveni locat throughout
unit state recogn brand prime
distribut channel solid variabl keep
econom moat stabl addit around store
acquir also expand geograph
market reach area littl presenc
addit market share help least stem
off-set aforement headwind
walgreen sought enhanc supplier
purchas power acquir allianc boot major
retail distributor
partner amerisourcebergen
pharmaceut distributor purchas half rite
aid retail locat opportun gain distribut
effici enhanc manufactur price leverag
relationship posit walgreen
howev partnership direct respons
price pressur firm face larg payer
opinion walgreen need off-set price pressur
lower reimburs rate payer build
supplier negoti power potenti gain better
manufactur price said total
convinc strateg move abl significantli
chang long-term trajectori firm abil
produc consist econom profit roic
posit influenc tactic believ
effici gain off-set price power drug
plan payer variabl consum discretionari
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
owalgreen largest retail pharmaci
network give firm abil reach
excel scale
opharmaceut spend grow solidli
next sever year given demograph shift
expans medic coverag mani uninsur
individu drive demand walgreen core back-
orec partnership potenti provid
improv result retail pharmaci
oth confluenc price pressur greater
competit mass grocer retail
heavi depend nonpharmaceut product
profit steadili push roic downward
owalgreen contend payer client base
signific price power thank power
posit major pbm
oth firm face increas direct competit
mass grocer retail believ
advantag reli conveni mild
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
walgreen oper decent level financi leverag
firm debt-to-ebitda ratio end
fiscal even though use signific portion
cash balanc acquisit approxim
store believ firm need
issu new debt believ firm abl rebuild
cash balanc without problem sinc assum
debt deal
main risk face walgreen price pressur
prescript benefit payer retail custom supplier
pharmaceut product even though firm struck
partnership tone player along drug
suppli chain anoth contract disput major pbm
could caus contract top- bottom-lin
result effect oligopoli firm
variabl even heighten given focu
mani drug plan payer significantli curb overal
narrow pharmaci network
addit signific portion walgreen result
depend consum discretionari spend
fluctuat materi econom cycl
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
share
fund
share
fund
stefano pessina firm major sharehold
ceo execut vice chairman sinc januari
posit undoubtedli given iron grip
firm perspect everi aspect
oper strategi driven pessina larg
view mani current sharehold compet
retail given earlier turnaround allianc boot
busi believ extens success
histori oper europ largest retail pharmaci
posit asset view pessina larg
european manag team underestim
nuanc healthcar retail market firm
struggl perform better part
last sever year retrench year-over-year
comp highlight firm struggl specif
concern firm strategi tri push sale
health beauti product given dynam
 consum skeptic strategi
nevertheless also believ certain strateg move
execut last year ad posit
walgreen long-term outlook notabl rite aid
acquisit enhanc firm overal retail oper
built effici distribut capabl
addit firm effect
manufactur price negoti power use
combin demand major retail firm
integr partnership also give
walgreen prime posit along pharmaceut
suppli chain move help bolster
distribut effici supplier negoti leverag
firm
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
walgreen anoth tough quarter contend
plethora issu jun
walgreen continu cope pressur reimburs
massiv consolid increas competit
prescript volum firm report increas
revenu third quarter on-board half
howev gross oper margin compress
basi point respect part profit margin
declin neg mix shift toward lower-profit
busi also believ firm still face
signific drug price pressur lacklust retail sale
 compstore fell retail good remain
flat pharmaci busi believ firm
struggl find foot rapidli chang healthcar
market need continu ration number
product sell level discount offer
regardless firm possess posit variabl
remain entrench posit along pharma
suppli chain thu reiter fair valu
coincident firm report earn amazon
announc purchas mail order pharmaci pillpack
move give amazon foothold drug suppli
chain logic step firm believ
retail pharmaci easiest segment suppli chain
new competit enter howev also believ
still tough firm creat major disrupt
given insur dynam drive market despit
market particip believ true end
custom insurers/employers/govern
pay health benefit consum accordingli
expertis need profit navig industri
preclud easi opportun new entrant believ
current downward stock price move fear
competit disrupt creat opportun investor
acquir solid moati firm drug wholesal
pbm industri discount
perspect three key variabl
overlook market particip
stakehold analyz potenti new meaning
competit within pharmaceut market
true custom along chain busi
provid health benefit consum provid
health benefit make almost decis regard drug
pharmaci access busi also sourc suppli
drug partnership togeth btob
market develop use drug health-
insurance-bas treat medic ailment
consumer-demand cash-pay market estim less
prescript paid consum
directli cash-pay basi without insur
dynam would take mani consumer-bas compani
built success within consumer-demand-driven
market outsid core compet
get involv pharmaceut space
price pharmaceut
drug price high-profil issu engulf
pharmaceut industri percept new
entrant amazon particular instantli come
cut price drug howev actual drug price
alreadi low given massiv amount buy power
pbm drug wholesal retail pharmaci
purchas power compar massiv joint-
sourc ventur develop past hand
year thu level gener drug discount
pale comparison major pharma suppli chain player
make difficult price-competit
access global suppli drug requir
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
viabl player within pbm pharma wholes
retail pharmaci space access everi legitim drug
requir due variabl demand health
insur product viabl pharma player need abl
access plethora drug
manufactur across world level access
achiev major drug market servic player
new entrant reach level
option clear major drug benefit provid
seller purchas pharmaceut
detail analysi competit dynam
pharmaceut space amazon potenti
disrupt pleas see report sell drug easier said
done moati pharma channel
choppi continu walgreen firm
search answer shift ket
walgreen struggl cope rapidli chang
pharmaceut market pressur reimburs
massiv consolid increas competit
prescript volum firm aggress pursu
strategi becom anchor pharmaci mani
narrow pbm pharmaci network possibl order
becom prefer pharmaci walgreen discount
gener drug suppli profit taken hit
result quarter differ firm report
total gross margin compress basi point
adjust gross margin oper
compress basi point order backfil
lower level pharmaceut profit manag
tri drive
increas sale front-of-the-stor
continu drag same-stor sale
categori fall manag mention
ration number product sell product
discount dynam like contribut
front-end product sale either neg
margin posit last sever quarter trend
concern fall line long-term outlook
retail pharmaci reiter no-moat
rate fair valu estim
player within pharmaceut space
entiti better known resid retail
pharmaci combin dynam prime retail
personnel need essenti core product would lead
one believ firm posit consist
produc econom profit howev believ walgreen
face steep long-term headwind struggl
margin compress firm discount drug
inventori order drive store traffic tri
drive front-stor sale off-set profit pressur
result last sever quarter indic
strategi yet show inde preserv grow
profit walgreen perspect firm
long-term profit outlook remain uncertain see long-
term challeng ahead retail pharmaci
perspect signific consolid among major
pharmaci variou shift strategi away
core pharmaceut sale major retail chain
underscor tighten oper environ
rumor walgreen want follow familiar
buy-out playbook amerisourc may go along
feb wall street journal report walgreen
recent approach acquir
drug distributor remain equiti walgreen
alreadi transact would vertic integr
drug distribut retail pharmaci space within
 fall line strategi walgreen
current manag team execut europ built
allianc boot busi news still press
report believ rumor substanti
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
past year walgreen partner integr
signific portion oper asset equiti
amerisourc thu total merger seem like next
logic step retail pharmaci particularli given
desir firm leadership vertic integr
busi howev believ amerisourc may
share sentiment assign amerisourc
wide moat rate assign walgreen no-moat
rate believ vertic integr would benefit
walgreen amerisourc accordingli
premium fair valu estim leav
moat rate fair valu estim place given
offici announc either
inform regard moat valuat
analysi walgreen amerisourc pleas
refer recent report healthcar observ
right prescript no-moat retail pharmaci
market sell drug easier said done moati
pharma channel healthcar observ under-valued
disrupt pbm mco wholesal jan
amazon berkshir hathaway jpmorgan
announc jan trio form independ
healthcar compani help control healthcar cost
 -base employe could
potenti given capit clout three partner
believ certain investor underappreci
moati natur healthcar suppli chain
formid competit advantag insul
signific headwind tri break vertic along
chain dynam healthcar market
difficult navig specul amazon
berkshir jp disrupt space leverag
impress capit war chest busi expertis
caus valuat pbm mco drug wholesal
retail pharmaci fall materi believ
stock price creat
opportun investor acquir solid wide-moat firm
discount would highlight express script
cardin particularli good
exact oper structur products/servic
ultim mandat partnership yet
develop partnership tri
sizabl corpor busi without major
chang within healthcar marketplac capit
manag clout three partner undoubtedli
great howev core-compet healthcar
relat take signific time legitim
oper develop addit believ potenti
new partnership would lack scale size provid
effici price power par major
healthcar servic firm especi case given
local densiti necessari obtain decent provid price
sourc joint ventur among retail pharmaci
drug distributor pharmaci benefit manag
combin number employe firm
close million initi may seem like give
partnership signific price power howev even
firm abl leverag entir million-person
employe base would pale comparison larg
healthcar servic firm equival small/mid-
tier insur estim combin number cover
live five major mco approxim
million live three larg pbm million
live respect thu price power new
partnership would garner significantli lower
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
healthcar servic firm built addit
mani employe trio base intern
hous independ oper like bring
total number one million potenti cover live
regul legal requir need effici
deliv healthcar extrem oner
absolut need consum safeti
would new entrant need compli variou feder
agenc claim regulatori jurisdict healthcar
servic product also countless state
municip foreign agenc licens regulatori
approv would take year new partnership fulli
compliant abl provid full-servic healthcar
servic employe administr work
wait period would also add signific time
regulatori approv process perspect amazon
berkshir jp new entrant healthcar
market would need partner one three larg
pbm one five larg mco order viabl
player within space
overview drug suppli chain would highlight
recent report sell drug easier said done
moati pharma channel analyz potenti
new competit within pharmaceut market
analysi wide moat exist space
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end august
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end august
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
